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Abstract
Background: Collapsing Glomerulopathy (CG), also known as the collapsing variant of Focal Segmental
Glomerulosclerosis (FSGS), is distinct in both its clinical severity and its pathophysiologic characteristics from
other forms of FSGS. This lesion occurs disproportionally in patients carrying two APOL1 risk alleles, and is the
classic histologic lesion resulting from Human Immunodeficiency Virus (HIV) infection of podocytes. Other viral
infections, including parvovirus B19, and drugs such as interferon that perturb the immune system, have also
been associated with CG. Despite significant advances, explaining such genetic and immune/infectious associations
with causative mechanisms and supporting evidence has proven challenging.
Case presentation: We report the case of a healthy (HIV-negative) pregnant 36 year-old Caribbean-American woman
who presented with nephrotic syndrome and fetal demise in the setting of acute parvovirus B19 infection. A series
of three renal biopsies and rapid clinical course showed progression from significant podocyte injury with mild light
microscopy findings to classic viral-associated CG to ESRD in less than 3 months. Genetic analysis revealed two APOL1 G1
risk alleles.
Conclusions: This is the first published case report of CG in the setting of acute parvovirus infection in a patient with
two APOL1 risk allelles, and parvoviral proteins identified in renal epithelium on kidney biopsy. These findings support
the causative role of parvovirus B19 infection in the development of CG on the background of APOL1 genetic risk.
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Background
Collapsing Glomerulopathy (CG) represents approxi-
mately 12 % of focal segmental glomerulosclerosis (FSGS)
histology and is more likely to present with nephrotic syn-
drome and rapid progression to end-stage renal disease
(ESRD) compared with other FSGS variants [1, 2]. While
other forms of FSGS have podocyte loss, glomerular epi-
thelial cells in CG show evidence of hyperplasia and
hypertrophy. In CG, there is a transition of typical markers
of mature podocytes to an expression profile more charac-
teristic of the parietal epithelial cells of Bowman’s capsule,
raising questions of the origin of the abnormal glomerular
epithelium [3]. These epithelial cells often appear swollen
and vacuolated, with totally effaced foot processes overly-
ing collapsed glomerular capillary loops, and may demon-
strate mitotic activity. Extra-glomerular manifestations of
CG, such as cystic tubular dilation, acute tubular injury
and occasionally interstitial nephritis, are also commonly
seen. Despite extensive research and some important ad-
vances in the field, the mechanisms resulting in this histo-
logic lesion remain poorly understood, and thus targeted
treatments do not yet exist.
Much of what is known about the pathogenesis of CG
comes from human case reports and animal models. How-
ever, finding a central theme is difficult. Animal models
suggest that HIV viral proteins, even when expressed only
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in podocytes, lead to both the glomerular and tubular char-
acteristics of this lesion on particular genetic backgrounds
[4]. Other animal models demonstrate CG resulting from
seemingly unrelated mechanisms such as mitochondrial
perturbations or oxidative stress [5]. Prior to the initiation
of widely available and effective antiretroviral therapy, CG
was the most common kidney lesion in HIV positive pa-
tients [6]. Importantly, other viruses besides HIV, particu-
larly parvovirus B19, have been associated with CG [7, 8],
as have medications such as interferon and pamidronate
[5, 9]. Taken together, this multiplicity of causes leading to
a unified phenotype highlights the need for further investi-
gation of the common, necessary, and sufficient renal in-
sults that result in this lesion.
The discovery of the association of APOL1 genetic var-
iants with FSGS and particularly HIV-associated Ne-
phropathy (HIVAN) (odds ratio 17 and 29 respectively)
has led to extensive effort to characterize the potential
role of the protein product of APOL1 [10]. This gene is
a member of the APOL gene family that arose recently
in evolution by gene duplication. It has been retained in
humans, and some African primates, because of its role
in lysis of trypanosomes [11]. The isoforms of APOL1
formed by the variants known as G1 and G2 seem to
have the added ability to lyse Trypanosoma rhodesiense
in addition to Trypanosoma brucei [11]. Its domain
structure, which includes a transmembrane chloride
channel, has been compared to bacterial colicins, diph-
theria toxin, and bcl-2, each of which lead to cell death
[12]. APOL1 is both a tissue and a secreted protein.
Based on observations that APOL1-related risk is af-
fected by the genotype of the donor kidney but not the
recipient of a renal transplant [13], it seems that the tis-
sue form is the one of relevance likely through cell toxic
effects. Protein and mRNA localization reveal APOL1
expression in podocytes, glomerular endothelial cells,
and tubular cells, but not mesangial cells [14]. There is
no formal assessment in the literature of expression of
APOL1 in parietal epithelial cells; however, images of
protein and mRNA localization seem to show absence
from the area of Bowman’s capsule [14, 15]. Notably, the
penetrance of the “at-risk” APOL1 genotype (homozy-
gous or compound heterozygous for G1 or G2 allele) for
kidney disease is much lower than that for other Men-
delian diseases. Of patients with this at-risk genotype,
only 4 % develop FSGS (however in the setting of un-
treated HIV infection, 50 % develop HIVAN) [10]. This
low penetrance of the phenotype among patients with this
genotype, coupled with undeniable association of the at-
risk APOL1 genotype with renal disease, suggests the need
for a “second hit” as well as a likely role for other genetic
or environmental factors. In this context, there may be a
role of the “nephrotropic” parvovirus B19 in disease
development.
Human parvovirus B19 is a small icosahedral ssDNA
virus whose genome encodes two capsid proteins, VP1
and VP2, and a non-structural protein, NS1 [16]. Most
adults worldwide show evidence of past infection, but
symptoms vary from nearly asymptomatic to severe, de-
pending on comorbidities and age at the time of primary
infection [17]. Typically, immunocompetent adult hosts
have very mild or asymptomatic disease, and are im-
mune after antibody response to primary infection. Early
symptoms of parvovirus infection result from death of
erythroid lineage cells leading to reticulopenia. In sus-
ceptible hosts, this results in a transient aplastic anemia
or hydrops fetalis. Later symptoms correspond to the de-
velopment of an immune response to the virus, which
may manifest as Fifth’s disease rash, gastrointestinal symp-
toms, or arthropathy [16]. Binding affinity of the capsid
proteins for globoside receptors on erythroid-lineage cells
leads to significant tropism of the virus for this cell type.
Studies have since identified globoside Gb4, and similar
glycosphingolipid receptors in numerous other tissue
types including the kidney [18]. This finding adds plausi-
bility to prior associations of hepatitis, myocarditis, and
glomerulopathy with parvovirus infection made solely on
temporal relation of viral infection and organ dysfunction
coupled with the detection of parvoviral DNA in affected
organ tissue.
Parvovirus B19 has been associated with CG for over
15 years, with several case reports demonstrating tem-
poral relationship between infection and CG in both na-
tive and transplanted kidneys, but without definitive
evidence of causality or explanation of its pathogenic
role [8, 19, 20]. Parvoviral DNA was detected in archived
kidney biopsies with a diagnosis of non-HIV related CG
significantly more often than in biopsies of other kidney
lesions [7, 8]. One of the two studies was able to localize
this parvoviral DNA to visceral and parietal epithelial
cells, as well as tubular cells. Seroprevalence (evidence
of past exposure) was higher in patients with such le-
sions as well [8]. However, the detection of parvoviral
DNA in approximately 25 % of both control samples
and other glomerular lesions questions the specificity of
this finding for disease pathogenesis. Experts in the field
have suggested that showing evidence of parvoviral pro-
teins in glomerular cells would help to prove infection
by the virus in these cells as opposed to passive exist-
ence of the viral genome [21].
This case report hopes to direct attention to the role
of the parvovirus B19 and APOL1 interaction in CG.
Case presentation
Initial presentation
A previously healthy 36 year-old Caribbean woman,
G4P2012, presented at 8 weeks gestation, with a 1-week
history of worsening swelling in her hands and feet. Her
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prior pregnancies were without complication, and she
took no medications other than prenatal vitamins. She
had no personal or family history of kidney disease or im-
munodeficiency. Her prenatal workup was unremarkable
and HIV test negative. Her physical exam on presentation
was significant for a blood pressure of 146/95 mmHg, and
3+ pitting edema up to her knees. Approximately 1 month
prior to presentation, her 4-year-old daughter had ex-
perienced a classic presentation of “Fifth disease” from
parvovirus B19. On admission, an obstetrical ultrasound
revealed fetal demise and she underwent a dilation and
curettage procedure. Products of conception were not
sent for parvovirus staining as the obstetrical team felt her
presentation was entirely consistent with acute parvovirus
infection.
Notable laboratory and imaging results included serum
creatinine concentration (SCr) of 557 umol/L (6.3 mg/dL),
blood urea nitrogen of 15.3 mmol/l (43 mg/dL), serum al-
bumin 15 g/L (1.5 g/dL), total cholesterol 10.55 mmol/L
(408 mg/dL), triglycerides 7.01 mmol/L (621 mg/dL), LDL
7.86 mmol/L (304 mg/dL), INR 0.96, PTT 33 s, and PT
10.7 s. A spot urine protein:creatinine ratio was 20.8 g/g.
Urine microscopy revealed 2–5 white blood cells per high
power field and maltese crosses were diffusely present
upon polarization. Further serologic workup was negative,
including ANA, anti-dsDNA, repeat HIV test, and for
hepatitis B and C. Serum parvovirus B19 qPCR detected
the parvoviral genome with a modest viral load of ap-
proximately 2000 copies, and parvovirus serologies both
IgM and IgG were elevated demonstrating acute infection.
While, “undetected” would be the reported result for
unexposed individuals, the clinical virology lab reports
that their sensitive qPCR assay allows for viral load quan-
tification from approximately 200 copies to over 1X1010
(with the higher values only seen in immunocomprom-
ised and sickle cell patients who present early and
without adequate immune response). Renal ultrasound
revealed normal sized kidneys bilaterally and slight
increase in echogenicity, but without hydronephrosis,
cysts, or calcifications.
Renal biopsy/diagnosis
The patient underwent renal biopsy (Fig. 1) on day 3 of
presentation, with a limited biopsy sample revealing 10
mostly unremarkable glomeruli aside from few swollen
and vacuolated podocytes found focally and segmentally.
There was acute tubular injury with simplification of
tubular epithelium, loss of brush border staining, and di-
lated tubular lumina, as well as a moderate interstitial in-
flammatory infiltrate without significant tubulointerstitial
scarring. Immunofluorescence was not done due to sam-
ple inadequacy. Electron microscopy demonstrated patent
capillary loops with minor basement membrane irregular-
ity, but no immune complex deposits or tubuloreticular
inclusions. There was global podocyte foot process efface-
ment. Immunohistochemistry for parvoviral proteins (Cell
Marque R29F6 mouse monoclonal antibody [22, 23],
1:100 dilution, with appropriate negative controls) was
performed after the time of clinical care, and demon-
strated positivity in hypertrophic podocytes, parietal epi-
thelial cells, and tubular cells (Fig. 2). Given her clinical
diagnosis of acute parvovirus infection, and the glomeru-
lar changes along with the microcystically dilated tubules,
the biopsy was interpreted as showing changes suggestive
of Collapsing Glomerulopathy with acute tubular injury
and mild active interstitial nephritis. The hope was that, if
attributable to parvovirus, this injury would improve with
self-limited resolution of viral infection over time. She was
treated with oral prednisone (60 mg daily) for the intersti-
tial nephritis. Her SCr did not improve, and peripheral
edema worsened despite diuretics. Two weeks later, she
was re-biopsied to determine a more definitive diagnosis.
A total of nine glomeruli were present, two segmentally
sclerotic with more pronounced podocyte hypertrophy
and hyperplasia, and prominent microcystically dilated tu-
bules. Immunofluorescence microscopy was performed
and was negative for immune reactants. A diagnosis of
CG, likely virally-mediated, was made.
Clinical progression
She was discharged home after 3 weeks of hospitalization,
with tapering prednisone and an aggressive diuretic regi-
men. She returned 6 days later with orthostatic hypotension
despite persistent anasarca (80+ pounds above her base-
line). Her serum albumin was 10 g/L (1.0 g/dL). Water
immersion therapy with diuresis was attempted in an effort
to alleviate the patient’s edema, but had little effect.
Her SCr had improved to 309 umol/L (3.5 mg/dl) by
5 weeks after presentation, but she then developed pan-
cytopenia. Serum hemoglobin fell to 50 g/L (5 g/dL),
platelet count to 15,000/uL, and ANC as low as 1700/uL
with an inadequate rise in reticulocyte count. Serum lac-
tate dehydrogenase and haptoglobin remained normal.
Bone marrow biopsy showed a markedly hypocellular
marrow with mild dyserythropoesis. While no viral in-
clusions or hemophagocystosis were found, her serum
ferritin rose to 2260 ug/L. This was proposed to be
from parvovirus-related inflammation, which has been
reported previously [24]. Repeat parvoviral testing
showed persistently detectable low levels of virus in
the 200–1000 copy range. Intravenous immunoglobu-
lin (IVIG) was started for multi-organ complications of
parvovirus, despite low copy numbers. Preparations of
IVIG contain parvovirus specific antibodies at concentra-
tions capable of neutralizing parvoviral antigens [23, 25]
and have been shown to be helpful in eradicating parvo-
virus B19-associated anemia [26, 27]. IVIG dosing was
empiric, and notably, most of the infusion was lost in the
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urine (proteinuria up to 60 g/day following infusion).
Dosing was continued at 1 g/kg every other day, and
eventually quantitative PCR showed estimated viral
copy number less than 200 copies, although persistently
detected. Because she had no initial response to the
IVIG and her pancytopenia was severe, she also re-
ceived intravenous solumedrol (60 mg daily for 2 weeks,
then tapering). After a total of 1 month of hematologic
issues, cell counts returned to normal. Initially after be-
ginning IVIG treatment, the SCr reached a nadir of 256
umol/L (2.9 mg/dl), but with her worsening pancyto-
penia, kidney function worsened, and SCr rose to over
530 umol/L (6 mg/dl).
A third renal biopsy was undertaken 10.5 weeks after
initial presentation to help decide whether to consider
cytotoxic therapy for FSGS in a now fairly debilitated
young woman. Due to the extent of disease progression
on this biopsy, the decision was made to forego any
cytotoxic therapy and to initiate dialysis for uremia and
volume management.
Fig. 1 Kidney biopsy images from initial presentation (a – 40x, b – 10x PAS), 2 weeks later (c – 40x Jones, d – 10x PAS, e – EM 8000x) and 2
months later (f – 40x, g – 10x PAS). At initial presentation, glomeruli have patent capillary loops with few hypertrophic vacuolated podocytes
(a - arrow). There is acute tubular injury and clusters of microcystically dilated tubules containing proteinaceous casts (b - arrow). Two weeks
later, glomeruli show more pronounced collapsing features with prominent vacuolated podocytes and capillary obliteration (c - arrow).
Microcystically dilated tubules remain with acute tubular injury and an increase in tubulointerstitial scarring (d). Electron microscopy
demonstrates extensive foot process effacement (e) without electron dense deposits or tubuloreticular inclusions. Two months after initial
presentation, advanced glomerular collapse and sclerosis are present with persistent focal and segmental epithelial cell hypertrophy and
hyperplasia (f - arrow), and dilated tubules with progressive tubulointerstitial scarring (g)
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Genetic analysis
Given the uncommon severity of this case and the possi-
bility of African ancestry given her Caribbean origin [28],
the possibility of a genetic susceptibility to podocyte injury
was considered. To investigate this, venous blood was col-
lected in the setting of an IRB-approved research protocol
and genomic DNA was extracted and sent for whole ex-
ome sequencing by Illumina HiSeq 2000 technology. The
authors used well validated scripts made available by the
Yale Genetics/Yale Center for Genomic Analysis [29] to
curate, align, and annotate the sequencing data. Mean
coverage was 57.4 reads, and there was 92.4 % 10x
coverage. As hypothesized may be the case, our patient
carries two APOL1 risk alleles (homozygous missense
variants p.S342G and p.I384M which together comprise
the G1 risk allele). For completeness, the following 50
additional genes with published association with glom-
erular diseases were also assessed: ACTN4, ADCK4, ALG1,
ALMS1, ANLN, APOA1, APOL1, ARHGAP24, ARHGDIA,
ATGB4, B2M, CD151, CD2AP, CFH, COL4A3, COL4A4,
COQ2, COQ6, CRB2, CUBN, DGKE1, EMP2, FGA, FN1,
GLA, INF2, ITGA3, ITGB4, LAMB2, LMX1B, LYZ, MEFV,
MYH9, MYO1E, NEIL1, NLRP3, NPHS1, NPHS2, PAX2,
PDSS2, PLCE1, PLCG2, PMM2, PTPRO, SCARB2,
Fig. 2 Parvovirus Capsid Protein Staining. Immunohistochemistry results on patient’s initial renal biopsy (day 3 of presentation) using primary antibody
to human parvovirus B19 capsid proteins VP1 and VP2 and anti-mouse-HRP secondary antibody. Strong positive staining indicated by arrows is noted
in the cytoplasm of hypertrophic podocytes (a original magnification x100), parietal epithelial cells (b original magnification x 100), and tubular
epithelium (c original magnification x 40). Negative staining in hyperplastic podocytes from a different case of collapsing glomerulopathy associated
with anabolic steroid use, stained as a negative control (d original magnification x 100). HIVAN and lupus associated collapsing podocytopathy cases
also stained negatively for parvovirus B19 (data not shown). Non-specific mouse IgG with same anti-mouse-HRP was used on additional section from
patient’s same biopsy as a negative control and was negative throughout the biopsy specimen (e original magnification x100, f original
magnification 40x)
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SMARCAL1, TRPC6, WDR73, WT1, ZMPSTE24. There
were no loss of function (nonsense, frameshift, splice site)
variants, nor were there any rare non-synonomous variants
with predicted deleterious consequence in these genes.
Subsequent follow-up
Over the subsequent 2 months on hemodialysis, the pa-
tient became anuric. Her serum albumin climbed to
3.0 g/L (by 5 months after her initial presentation). She
was evaluated for transplantation, and successfully re-
ceived a living donor kidney transplant from her sister
8.5 months after initial presentation and 6 months after
starting hemodialysis. Our findings of the patient’s
APOL1 genotype were made available to transplant phy-
sicians during transplant evaluation and clinical genetic
testing was suggested to the patient’s donor (sister) but
she declined. As there are no established guidelines in
place for APOL1 testing of donor organs, the donation
was accepted. With over 6 months of follow-up, her renal
function fortunately remains excellent, with <500 mg pro-
teinuria, and no anemia.
Discussion/Conclusions
This case report adhered to CARE (Additional file 1)
guidelines for reporting case reports. This case broadens
existing evidence that acute parvovirus infection can
lead to CG in individuals at risk due to APOL1 genotype.
It remains to be seen if the APOL1 at-risk genotype is
essential for development of this lesion following parvo-
virus infection. Importantly, CG is not the only renal le-
sion seen in those with the at-risk APOL1 risk genotype
[30], so other genetic or environmental factors likely
play a role in determining what renal lesion, if any, a
particular patient will get. While it was initially difficult
to describe a unifying explanation for all of the human
and animal model findings regarding the pathogenesis of
CG, the potential interaction between viruses and
APOL1 may finally be coming into focus. There are ac-
cumulating data suggesting that the interferon-mediated
response to viruses may increase production of a cell-
toxic APOL1 variant protein.
Eleven cases of CG following interferon treatment given
for a different medical conditions have been reported [9],
and genotyping recently was provided for 7 of these pa-
tients, all of whom carried two APOL1 risk alleles [31].
Nichols et al characterized this association further by dem-
onstrating that interferon exposure up-regulates wild-type
and risk-variant APOL1 transcription, including produc-
tion of alternative transcripts [31]. Moreover, HEK cells
transfected with G1 or G2 genotypes of APOL1 transcripts
showed increased cytotoxicity/viability ratio compared to
the wild-type genotype. Indeed, other investigators have
found that risk variant APOL1 proteins have cell lytic
capabilities due to lysosomal membrane pore forming
function perturbing vesicular trafficking, and could cause
podocyte injury in vitro and hepatocyte necrosis in vivo
[32]. Taken together, these findings suggest that interferon
stimulation in a patient with APOL1 risk alleles leads to
increased production of a cell-toxic protein [31]. The pro-
posed connection of this finding with viral infection is the
interferon. Similar to the immune response for many vi-
ruses [33], review of the literature suggests that the typical
immune response to parvovirus involves a necessary and
lasting antibody response to parvoviral capsid proteins as
well as recruitment of a TH1 T-cell response, which in-
cludes production of cytokines such as interferon gamma
[34–36]. While this hypothesis is appealing, it seems that
with >10 % of African Americans carrying this at-risk
APOL1 genotype, simple systemic immune response to
relatively common viral infections should make CG more
prevalent than it is [37]. It is also important to note that
Divers et al [38] showed that exposure to JC virus had a
protective influence in patients with APOL1 risk variants
[39], so not all viruses have the same effect. Likely an exag-
gerated immune response, additional kidney insults, or
more direct kidney targeting (i.e. direct infection of podo-
cytes by parvovirus or HIV) of immune responses is
necessary. The identification of parvoviral proteins in af-
fected renal epithelial cells (Fig. 2) demonstrates viral tran-
scription/translation rather than just passive existence of
genomic material. This supports a role for direct viral in-
fection of these cells preceding renal disease.
Our patient’s immune response to parvovirus may have
been atypical. Firstly, her significant associated symptoms
(hydrops fetalis, pancytopenia, and CG) are more severe
than expected in an immunocompetent host. Secondly,
this occurred in the setting of a low viral load during acute
infection. Her viral load failed to clear promptly; however,
it has been suggested that parvovirus DNA can be de-
tected for months to years after acute infection in a normal
person [16]. Worth noting is the potential role pregnancy
may play on immune modulation in this case. Further-
more, while our hematology consultants were left puzzled
as to the precise etiology of her profound pancytopenia
that lasted several weeks, they considered it to be an
inflammatory reaction in the spectrum of Hemophagocytic
Lymphohistiocytosis, a disease process in which interferon
gamma production is thought to be central.
This case provides evidence of parvoviral proteins in
renal epithelial cells and a strong case for the role of
parvovirus B19 infection in the pathogenesis of CG in a
patient genotyped to show homozygous APOL1 G1 risk
alleles. We believe that with parvovirus B19 infection
identified as one potential “second hit” in those with
APOL1 risk alleles, perhaps clinical consideration of si-
lent infection in other cases of “idiopathic” CG should
be considered to aid in further data accumulation on
this fascinating topic.
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